Why the AVITA (ASX:AVH) share price is charging higher today

The AVITA Medical Inc (ASX:AVH) share price is on the move on Friday following the release of its third quarter update…

| More on:
ASX shares profit upgrade chart showing growth

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The AVITA Medical Inc (ASX: AVH) share price is on the move on Friday morning.

At the time of writing, the regenerative medicine company's shares are up 4% to $5.35.

Why is the AVITA share price charging higher?

Investors have been buying the company's shares this morning following the release of its third quarter update.

According to the release, demand for the company's Recell system rebounded strongly during the quarter.

This led to AVITA recording revenue of US$8.8 million for the three months ended 31 March, which was a 126% increase over the prior corresponding period. Positively, this was also a 72.5% increase on its second quarter revenue.

Supporting this growth was an increase in procedural volumes. For the quarter, volumes reached 492. This compares to 408 in the prior corresponding period and 487 in the second quarter.

AVITA also advised that it added 6 new burn centre accounts during the three months, lifting its total to 99. This represents a penetration rate of 73% of the 136 total U.S. burn centres.

Furthermore, of the approximate 300 total U.S. burn surgeons, 244 have now been trained and certified with Recell. And 147 of these surgeons used Recell during the quarter.

Margins

AVITA's gross margin has softened over the last 12 months from 84% to 76%. This reflects a lower Recell price point for units that were purchased under contract with BARDA. The company's contract with BARDA was negotiated prior to the establishment of a higher price point achieved in the Recell commercialisation in the United States.

Positively, the company offset this with a reduction in its operating expenses. They came in at US$13.2 million for the third quarter, which is down from US$19.7 million a year earlier. Management advised that this was primarily attributable to lower stock-based compensation along with lower sales and marketing expenses.

Nevertheless, this wasn't enough to stop AVITA from recording a quarterly net loss of US$6 million. Though, this is a big improvement on last year's third quarter loss of US$15 million.

This left the company with cash of US$114.9 million at the end of the period.

Q4 guidance

Management advised that total revenue is expected to be in the range of US$8.2 million to US$8.6 million in the fourth quarter.

This comprises US$5 million to US$5.3 million of commercial Recell revenue and US$3.2 million to US$3.3 million of Recell revenue associated with BARDA.

AVITA's Chief Executive Officer, Dr. Mike Perry, said: "We made steady progress over the last quarter as we continued to drive RECELL usage in our established hospital burn center base with an increasing focus on smaller burns, and we continued to expand our physician training and outreach programs. As pandemic headwinds abate, we plan to leverage our highly experienced burns sales force and strong relationships built to date with the burn practitioner community to increase hospital access and to penetrate deeper into our existing accounts, resulting in additional procedures and engaging more burn practitioners."

"Our three pivotal clinical trials in vitiligo, trauma, and pediatric burns are continuing on schedule and we expect to see expanded indications for RECELL coming online, allowing us to serve an ever-growing population of patients," he added.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Rising gold share price represented by a green arrow on piles of gold block.
Gold

3 reasons to buy this surging ASX All Ords gold stock today

The ASX All Ords gold stock has doubled investors’ money in 12 months, and this leading expert forecasts more outperformance…

Read more »

Two colleagues at work looking at a tablet and smiling at a rising share price.
Share Gainers

Why Generation Development, Orica, Pro Medicus, and Zip shares are storming higher today

These shares are having a strong session on Thursday. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 114% in a year, why is the Pro Medicus share price leaping higher again on Thursday?

Pro Medicus shares are back in form today and leaping ahead. Here’s why.

Read more »

Man standing on rock next to turquoise salt lagoon.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX 200 finally had a green session this hump day.

Read more »

Man pointing at a blue rising share price graph.
Share Gainers

Guess which ASX 300 stock just rocketed 17%!

Investors are sending the ASX 300 stock soaring higher on Wednesday. But why?

Read more »

A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
Share Gainers

Why Firefly, Kelsian, NAB, and Zip shares are roaring higher today

These shares are having a good time on hump day. Let's find out why.

Read more »

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another tough day for investors this Tuesday.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Dimerix, Evolution Mining, Inghams, and NextDC shares are charging higher today

These shares are rising when many are falling today. But why?

Read more »